Natixis Advisors LLC Acquires 43,099 Shares of Avantor, Inc. (NYSE:AVTR)

Natixis Advisors LLC grew its position in Avantor, Inc. (NYSE:AVTR - Free Report) by 9.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 497,523 shares of the company's stock after buying an additional 43,099 shares during the quarter. Natixis Advisors LLC owned 0.07% of Avantor worth $12,871,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Swedbank AB purchased a new position in Avantor in the 1st quarter valued at about $2,707,000. Sound Shore Management Inc. CT acquired a new stake in shares of Avantor during the second quarter worth $76,412,000. Seven Eight Capital LP purchased a new position in Avantor during the second quarter worth about $642,000. New York State Teachers Retirement System purchased a new position in shares of Avantor during the 3rd quarter worth about $8,473,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in Avantor by 35.1% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,157,855 shares of the company's stock valued at $24,547,000 after purchasing an additional 300,579 shares during the period. Institutional investors and hedge funds own 95.08% of the company's stock.

Avantor Stock Down 0.2 %

Avantor stock opened at $20.10 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. Avantor, Inc. has a 1-year low of $19.59 and a 1-year high of $28.00. The firm's fifty day simple moving average is $24.14 and its 200-day simple moving average is $23.91. The company has a market capitalization of $13.68 billion, a P/E ratio of 43.78, a P/E/G ratio of 2.39 and a beta of 1.35.

Insider Buying and Selling

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the sale, the chief accounting officer now owns 29,544 shares in the company, valued at $740,372.64. The trade was a 10.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

AVTR has been the subject of a number of research reports. Royal Bank of Canada reissued an "outperform" rating and set a $34.00 price target on shares of Avantor in a research report on Thursday, September 26th. Barclays decreased their price target on Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Friday, October 25th. UBS Group lowered their price target on shares of Avantor from $30.00 to $29.00 and set a "buy" rating for the company in a report on Tuesday, October 8th. Stifel Nicolaus lifted their target price on Avantor from $27.00 to $28.00 and gave the stock a "buy" rating in a research report on Monday, July 29th. Finally, Robert W. Baird reduced their target price on Avantor from $27.00 to $26.00 and set an "outperform" rating for the company in a research note on Monday, October 28th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $27.57.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.